Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

PURPOSE: There is evidence from nonrandomized studies that a proportion of ipilimumab-treated patients with advanced melanoma experience long-term survival. To demonstrate a long-term survival benefit with ipilimumab, we evaluated the 5-year survival rates of patients treated in a randomized, contro...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Maio, Michele, Grob, Jean-Jacques, Aamdal, Steinar, Bondarenko, Igor, Robert, Caroline, Thomas, Luc, Garbe, Claus, Chiarion-Sileni, Vanna, Testori, Alessandro, Chen, Tai-Tsang, Tschaika, Marina, Wolchok, Jedd D.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5795709/
https://ncbi.nlm.nih.gov/pubmed/25713437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.6018
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky